Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors.

PURPOSE To prospectively correlate multidetector computed tomographic (CT) perfusion measurement of pancreatic endocrine tumors with tumor microvascular density (MVD) assessed by using histologic techniques and to determine whether perfusion CT parameters differ between tumor grades. MATERIALS AND METHODS Institutional review board approval and informed consent were obtained. Thirty-six patients (15 men, 21 women; mean age, 53 years; range, 18-78 years) with resectable pancreatic endocrine tumors underwent presurgical dynamic perfusion CT. Twenty-eight (78%) of 36 patients were included in the study group; eight were excluded because of artifacts that were not compatible with perfusion postprocessing. Multidetector CT perfusion data were analyzed to calculate tumor and normal pancreatic blood flow, blood volume, mean transit time, and permeability-surface area product. Multidetector CT perfusion parameters were compared with intratumoral MVD by using the Spearman correlation coefficient and with World Health Organization (WHO) classification, tumor size, tumor proliferation index, hormonal profile, and presence of metastases by using Mann-Whitney tests. RESULTS High correlation (r = 0.620, P < .001) was observed between tumor blood flow and intratumoral MVD. Blood flow was significantly higher (P = .02) in the group of benign tumors (WHO 1) than in the groups of tumors of indeterminate prognosis (WHO 2) or well-differentiated carcinomas (WHO 3). Blood flow was significantly higher in tumors with a proliferation index of 2% or less (P = .005) and in those without histologic signs of microscopic vascular involvement (P = .008). Mean transit time was longer in tumors with lymph node (P = .02) or liver (P = .05) metastasis. CONCLUSION Perfusion CT is feasible in patients with pancreatic endocrine tumors and reflects MVD. Perfusion CT measurements are correlated with histoprognostic factors, such as proliferation index and WHO classification.

[1]  Y. Kanai,et al.  Prognostic Value of Tumor Architecture, Tumor-Associated Vascular Characteristics, and Expression of Angiogenic Molecules in Pancreatic Endocrine Tumors , 2007, Clinical Cancer Research.

[2]  K. Miles,et al.  Perfusion CT for the assessment of tumour vascularity: which protocol? , 2003, The British journal of radiology.

[3]  C. Proye.  Endocrine tumours of the pancreas: an update. , 1998, The Australian and New Zealand journal of surgery.

[4]  B. Weinhold.  Epigenetics: The Science of Change , 2006, Virchows Archiv.

[5]  T-Y Lee,et al.  CT imaging of angiogenesis. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[6]  L. Kvols,et al.  Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma , 2007, Neuroendocrinology.

[7]  Stephen B. Fox,et al.  COMMENTARY Tumour angiogenesis and prognosis , 1997, Histopathology.

[8]  J. Mosnier,et al.  The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. , 1998, American journal of clinical pathology.

[9]  E. van Marck,et al.  Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  D. Sahani,et al.  Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. , 2005, Radiology.

[11]  K. Miles,et al.  CT measurement of perfusion and permeability within lymphoma masses and its ability to assess grade, activity, and chemotherapeutic response. , 1999, Journal of computer assisted tomography.

[12]  M. Jinzaki,et al.  Double-Phase Helical CT of Small Renal Parenchymal Neoplasms: Correlation with Pathologic Findings and Tumor Angiogenesis , 2000, Journal of computer assisted tomography.

[13]  S. Fox.  Tumour angiogenesis and prognosis. , 1997, Histopathology.

[14]  R. Craen,et al.  A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps. , 2000, AJNR. American journal of neuroradiology.

[15]  L. Ellis,et al.  Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. , 1998, European journal of cancer.

[16]  K Miyasaka,et al.  Tumor Angiogenesis and Dynamic CT in Lung Adenocarcinoma: Radiologic–Pathologic Correlation , 2001, Journal of computer assisted tomography.

[17]  J. Miller,et al.  Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. , 1998, The Journal of thoracic and cardiovascular surgery.

[18]  N. Holalkere,et al.  Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. , 2007, Radiology.

[19]  A. Harris,et al.  Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression , 2004, British Journal of Cancer.

[20]  R. Zimmerman,et al.  Reproducibility of postprocessing of quantitative CT perfusion maps. , 2007, AJR. American journal of roentgenology.

[21]  F. Pilleul,et al.  Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. , 2003, Gastroenterology.

[22]  L. Tanoue.  Computed Tomography — An Increasing Source of Radiation Exposure , 2009 .

[23]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[24]  T. Purdie,et al.  Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumour. , 2001, Physics in medicine and biology.

[25]  F. Sessa,et al.  Prognostic criteria in nonfunctioning pancreatic endocrine tumours , 1996, Virchows Archiv.

[26]  Zheng-yu Jin,et al.  [Perfusion characteristics of normal pancreas and insulinoma on multi-slice spiral CT]. , 2006, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.

[27]  T. Murakami,et al.  Quantitative tissue blood flow evaluation of pancreatic tumor: comparison between xenon CT technique and perfusion CT technique based on deconvolution analysis. , 2005, Radiation medicine.

[28]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[29]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[30]  K. Horton,et al.  Multi-detector row CT of pancreatic islet cell tumors. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[31]  S. Goldberg,et al.  CT perfusion for determination of pharmacologically mediated blood flow changes in an animal tumor model. , 2007, Radiology.

[32]  K. Miles,et al.  Perfusion CT: a worthwhile enhancement? , 2003, The British journal of radiology.

[33]  V. Vilgrain,et al.  Endocrine Pancreatic Tumours and Helical CT: Contrast Enhancement Is Correlated with Microvascular Density, Histoprognostic Factors and Survival , 2006, Pancreatology.

[34]  M. Falconi,et al.  Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization , 2001, European Radiology.

[35]  A. Levy.  Differentiation between Diverticulitis and Colorectal Cancer: Quantitative CT Perfusion Measurements versus Morphologic Criteria—Initial Experience , 2008 .

[36]  I. Francis,et al.  Dual-phase helical CT of nonfunctioning islet cell tumors. , 1998, Journal of computer assisted tomography.